ImmunityBio (IBRX) Income from Non-Controlling Interests (2017 - 2026)
ImmunityBio (IBRX) posted quarterly Income from Non-Controlling Interests of -$15000.0 for Q1 2026, up 25.0% year-over-year from -$12000.0 in Q1 2025, and down 7.14% quarter-over-quarter from -$14000.0 in Q4 2025.
Powered by 
Analysis
ImmunityBio (IBRX) Income from Non-Controlling Interests (2017 - 2026) Analysis & Trends
ImmunityBio (IBRX) has reported Income from Non-Controlling Interests for 10 consecutive years, with -$15000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 25.0% year-over-year to -$15000.0; the TTM figure through Mar 2026 stood at -$69000.0 (up 13.75% YoY), while the FY2025 annual figure was -$74000.0, up 8.64% from the prior year.
- Income from Non-Controlling Interests eased to -$15000.0 in Q1 2026 per IBRX's latest filing, from -$14000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$14000.0 in Q4 2025 and bottomed at -$334000.0 in Q2 2023.
- Historically, Income from Non-Controlling Interests has averaged -$92882.4 across 5 years, with a median of -$22000.0 in 2023.
- Annual changes were most pronounced in 2023 — Income from Non-Controlling Interests tumbled 39.53% — and 2024, when it jumped 94.01%.
- ImmunityBio's Income from Non-Controlling Interests stood at -$111000.0 in 2022, then surged by 80.18% to -$22000.0 in 2023, then climbed by 22.73% to -$17000.0 in 2024, then increased by 17.65% to -$14000.0 in 2025, then retreated by 7.14% to -$15000.0 in 2026.
- Business Quant data shows IBRX's Income from Non-Controlling Interests at -$15000.0 in Q1 2026, -$14000.0 in Q4 2025, and -$21000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | ImmunityBio | 8.52 Bn | 8.16 Bn | 50.94 Mn | -12,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -12,000.00 |
| Mar 31, 2026 | -15,000.00 |
| Dec 31, 2025 | -14,000.00 |
| Sep 30, 2025 | -21,000.00 |
| Jun 30, 2025 | -19,000.00 |
| Mar 31, 2025 | -20,000.00 |
| Dec 31, 2024 | -17,000.00 |
| Sep 30, 2024 | -23,000.00 |
| Jun 30, 2024 | -20,000.00 |
| Mar 31, 2024 | -21,000.00 |
| Dec 31, 2023 | -22,000.00 |
| Sep 30, 2023 | -60,000.00 |
| Jun 30, 2023 | -334,000.00 |
| Mar 31, 2023 | -240,000.00 |
| Dec 31, 2022 | -111,000.00 |
| Sep 30, 2022 | -223,000.00 |
| Jun 30, 2022 | -247,000.00 |
| Mar 31, 2022 | -172,000.00 |
| Dec 31, 2021 | -294,000.00 |
| Sep 30, 2021 | -800,000.00 |